Carlyle to buy 20% of Piramal's India pharma business
The Carlyle Group has agreed to invest approximately $490 million for a 20% stake in pharmaceutical division of India’s Piramal Enterprises, which has interests ranging from outsourced drug development to an ophthalmology joint venture with Allergan.
The transaction values Piramal Pharma at $2.78 billion, with an upside component of up to $360 million depending on the company’s performance over the coming year, according to a statement. The size...
More on South Asia
Latest News
Chinese online art tutoring platform secures $40m
Meishubao, China’s leading online art education platform, has raised $40 million in an extended Series C round led by Tencent Holdings.
Sequoia leads $100m Series C for China's Kuaidian
Kuaidian, a Chinese interactive content provider, has raised close to $100 million in Series C funding led by Sequoia Capital China. Existing investors GGV Capital and Morningside Venture Capital re-upped.
Warburg Pincus set for part-exit from Jinxin Fertility
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA looks to connect wealthy investors with unicorns
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.